INVERSAGO-PHARMA
17.5.2022 08:02:14 CEST | Business Wire | Press release
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, today announces the appointment of Glenn S. Vraniak to the position of Chief Financial Officer (CFO), effective immediately.
Mr. Vraniak’s career spans more than 20 years of financial and commercial experience in the life sciences industry. Before joining Inversago, Mr. Vraniak served as Chief Financial Officer of Evaxion Biotech A/S, an AI enabled immuno-oncology company and led the company through a successful IPO on Nasdaq in February 2021, and successfully raised follow-on capital later that same year. Prior to that, Mr. Vraniak served as the Chief Financial Officer of electroCore, Inc. and was a key member of the management team that led the company through a successful IPO on Nasdaq in June 2018. Additionally, Mr. Vraniak served as an executive in various innovative healthcare and technology companies including GE Capital, where he served as Executive Vice President.
“Glenn’s cumulative experience as CFO for several life science companies is a great asset, being well versed in preparing and executing corporate transactions and implementing financial frameworks for rapidly growing organizations like Inversago,” declared Mr. François Ravenelle, PhD, Chief Executive Officer. “We welcome him to our leadership team, and are excited to count on his expertise to reach future corporate milestones together.”
“It’s a real pleasure to join Francois and the rest of the team at Inversago at such an exciting time with a pipeline of unique compounds addressing unmet medical needs,” added Mr. Vraniak. “I look forward to contributing to the company’s growth in the months ahead.”
Mr. Vraniak received an Electronic Engineering Technology degree and a Managerial MBA in Finance from the Rutgers University Center for Management Development.
About Inversago Pharma
Located in Montreal, Inversago Pharma is a privately owned Canadian biotech company at clinical stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally acting CB1 inverse agonists. Inversago aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Nephropathy (DN), Non-Alcoholic Steatohepatitis (NASH), complications from obesity, Hypertriglyceridemia (HTG), Type 1 Diabetes (T1D) and Prader-Willi Syndrome (PWS), as well as fibrotic indications like Progressive Fibrosis-Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF). For more information, please visit inversago.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220516006056/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ireland Takes Centre Stage as MICHELIN Awards Come to Dublin for the First Time10.2.2026 12:06:00 CET | Press release
Ireland’s reputation as a world-class culinary destination was celebrated this evening as the MICHELIN Guide UK & Ireland Awards were held in Ireland for the very first time, celebrating the country’s exceptional chefs, restaurants and producers on an international stage. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260209670808/en/ Fôret Restaurant, Dublin At a ceremony hosted in Dublin, MICHELIN unveiled its latest selection for the UK & Ireland, with a number of Irish restaurants recognised for their creativity, craftsmanship and commitment to quality, marking a significant moment for Ireland’s evolving food scene and its growing appeal among international diners. The ceremony included the announcement of the MICHELIN Stars, the Bib Gourmands for great value dining, and a series of Special Awards recognising outstanding individuals and teams in hospitality. Eight Irish restaurants were awarded in total at the ceremony.
MultiBank Group Launches 50% Rebate Boost for IBs & 25% Deposit Bonus for Clients10.2.2026 11:43:00 CET | Press release
MultiBank Group, one of the world’s largest and most regulated financial derivatives institution, has announced the launch of two limited-time promotional programs designed to reward both its Introducing Broker network and retail trading clients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260210880239/en/ MultiBank Group has announced the launch of two limited-time promotional programs designed to reward both its Introducing Broker network and retail trading clients. The programs reflect the firm's ongoing strategy to strengthen relationships across its partner and client ecosystem while maintaining the competitive positioning that has supported the Group's growth since its establishment in 2005. Elite IB Promo: Enhanced Partner Compensation Under the Elite IB Promotion, MultiBank Group's Introducing Brokers are eligible to receive a 50% boost on their standard rebate and commission structures. The program provides IBs t
IEO and Laife Reply Join Forces to Digitalise the Biobank Through Artificial Intelligence10.2.2026 10:00:00 CET | Press release
The two partners launch “Bianca”, the first large-scale digitalisation initiative in Italy focused on histopathological samples, aimed at training AI algorithms to support pathologists’ diagnostic activities. The Pathology Division of the European Institute of Oncology (IEO) and Laife Reply, the Reply Group company specialised in AI and Big Data solutions for the healthcare sector, have entered into a collaboration to develop Bianca, the first project in Italy aimed at creating an AI-based digital biobank designed as an integral part of clinical diagnostic practice. The initiative is part of a broader technological innovation journey that structurally integrates research and development into routine diagnostic processes in pathology, transforming the traditional histopathological sample workflow into an end-to-end digital ecosystem. The complete digitalisation of histopathological and molecular diagnostic workflows aims to make analysis more efficient, scalable and reproducible, laying
OPEX® Corporation Introduces the Velo™ Series of Premium Desktop and High Production Document Scanners10.2.2026 10:00:00 CET | Press release
OPEX® Corporation, a global leader in Next Generation Automation providing innovative solutions for warehouse, document and mail automation, has announced the launch of its Velo™ Series powered by InoTec, a new class of premium desktop and free standing high production scanners. The OPEX Velo scanners are engineered to deliver exceptional performance, reliability and image quality and offer industry-standard TWAIN/ISIS connectivity to help simplify deployment into existing capture environments. These state-of-the-art scanners are ideal for service bureaus, government agencies, healthcare providers and enterprise capture operations. “The Velo Series powered by InoTec introduces an entirely new class of scanners to the OPEX portfolio, expanding the options available to both our current customers and organizations considering OPEX for the first time,” said Dann Worrell, President, Document and Mail Automation, OPEX. “By broadening our offerings, we can better align the right solution with
New ZOLL Zenix Monitor/Defibrillator Receives MDR Approval10.2.2026 10:00:00 CET | Press release
ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that Zenix®, the company’s most clinically advanced and easy-to-use professional monitor/defibrillator, is approved under the European Union (EU) Medical Device Regulation 2017/745, commonly referred to as EU MDR. The Zenix monitor/defibrillator is a groundbreaking device that redefines efficiency, clarity, and intelligence in both EMS and hospital settings. Built from years of feedback from customers, Zenix combines intuitive design with powerful functionality to enhance patient care and automate workflows for ease-of-use. Featuring a large, durable touchscreen, Zenix provides critical information when it’s needed. With on-the-fly customization, healthcare professionals can make real-time adjustments, helping them stay in control during high-pressure situations. Equipped with ZOLL’s innovative Real BVM Help® and exclusive Real CPR Help® technology, Zenix gives healthcare pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom